P0150: A precision medicine approach for carriers of defined IL2RA polymorphism: JAK inhibition blocks exaggerated IL-2 signalling in vitro, with no difference in in vivo clinical response rates in a small clinical cohortECCO'25Year: 2025
Authors: Clough, J.(1)*;Honap, S.(2);Centritto, A.(3);Seah, D.(4);Jayasena, H.(5);Irving, P.(3);Lord, G.(6);
(1)Kingston Hospital NHS Foundation Trust, Gastroenterology, LONDON, United Kingdom;(2)St George's NHS Foundation Trust, Gastroenterology, London, United Kingdom;(3)Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom;(4)Monash Health, Gastroenterology and Hepatology, Melbourne, Australia;(5)University Hospital KDU, Gastroenterology, Colombo, Sri Lanka;(6)King's Health Partners, King's Health Partners, London, United Kingdom;
1. Goldberg R, Clough JN, Roberts LB, et al. A Crohn’s disease-associated IL2RA enhancer variant determines the balance of T cell immunity by regulating responsiveness to IL-2 signaling. J Crohn’s Colitis. June 2021. doi:10.1093/ecco-jcc/jjab103
2. Parkes M, IBD BioResource Investigators. IBD BioResource: an open-access platform of 25 000 patients to accelerate research in Crohn’s and Colitis. Gut. July 2019:gutjnl-2019-318835. doi:10.1136/gutjnl-2019-318835
P0151: Multi-modal single cell sequencing identifies CCR9 expression in lamina propria with highest protein expression on CD4 tissue resident memory cells in the inflamed ileum in Crohn’s diseaseECCO'25Year: 2025
Authors: Hamilton, R.(1);Collin, J.(2);Keith, B.(3);Gehrmann, U.(4);Lindkvist, B.(5);Lundin, S.(4);Eberhardson, M.(6);Marks, D.(7);Platt, A.(1);Muthas, D.(4);Corridoni, D.(8);Bouma, G.(1)*;
(1)AstraZeneca, Translational Science & Experimental Medicine- Research and Early Development- Respiratory and Immunology R&I- BioPharmaceuticals R&D, Cambridge, United Kingdom;(2)AstraZeneca, Centre for Genomic Research- Discovery Sciences- BioPharmaceuticals R&D, Gothenburg, Sweden;(3)AstraZeneca, Data Science & Quantitative Biology- Discovery Sciences- BioPharmaceuticals R&D, Gothenburg, Sweden;(4)AstraZeneca, Translational Science & Experimental Medicine- Research and Early Development- Respiratory and Immunology R&I- BioPharmaceuticals R&D, Gothenburg, Sweden;(5)Sahlgrenska University Hospital, Department of Gastroenterology, Gothenburg, Sweden;(6)AstraZeneca, Early Clinical Development- Respiratory and Immunology R&I- BioPharmaceuticals R&D, Gothenburg, Sweden;(7)AstraZeneca, Early Clinical Development- Respiratory and Immunology R&I- BioPharmaceuticals R&D, Cambridge, United Kingdom;(8)AstraZeneca, Bioscience Immunology- Respiratory and Immunology R&I- BioPharmaceuticals R&D, Cambridge, United Kingdom;
P0152: Distinct faecal metabolic profiles associated with endoscopic remission in ulcerative colitis patients following faecal microbiota transplantationECCO'25Year: 2025
Authors: Jiwa, F.(1)*;Jitsumara, M.(2);Hugo, S.(3);Takis, P.(4);Ghiboub, M.(5);Kinross, J.(3);Harris, D.(6);Hitchings, M.(7);
(1)Amsterdam UMC, Department of Gastroenterology, Amsterdam, The Netherlands;(2)Royal Bournemouth Hospital, Colorectal and General Surgery department, Dorset, United Kingdom;(3)Imperial College London, Department of Surgery and Cancer, London, United Kingdom;(4)Imperial College London, Department of Metabolism- Digestion and Reproduction, London, United Kingdom;(5)Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology Endocrinology and Metab, Amsterdam, The Netherlands;(6)Singleton Hospital, Department of Colorectal Surgery, Swansea, United Kingdom;(7)Swansea University Medical School, Medical Microbiology and Infectious Diseases, Swansea, United Kingdom;
1. Imdad A, Pandit NG, Zaman M, Minkoff NZ, Tanner-Smith EE, Gomez-Duarte OG, et al. Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database Syst Rev. 2023;4(4):Cd012774.
2. Oancea I, Movva R, Das I, Aguirre de Cárcer D, Schreiber V, Yang Y, et al. Colonic microbiota can promote rapid local improvement of murine colitis by thioguanine independently of T lymphocytes and host metabolism. Gut. 2017;66(1):59-69.
3. Crittenden S, Cheyne A, Adams A, Forster T, Robb CT, Felton J, et al. Purine metabolism controls innate lymphoid cell function and protects against intestinal injury. Immunol Cell Biol. 2018;96(10):1049-59.
P0153: The role of the proglucagon-derived peptide GLP-2 in resection-triggered growth and barrier response in miceECCO'25Year: 2025
Authors: Mohebali, N.(1)*;Witte , M.(2);Berlin, P.(1);Lamprecht, G.(1);Reiner, J.(1);
(1)Rostock University Medical Center, Division of Gastroenterology and Endocrinology- Department of Medicine II, Rostock, Germany;(2)Rostock University Medical Center, Department of General- Visceral- Thoracic- Vascular and Transplant Surgery, Rostock, Germany;
P0155: Investigating the effect of a novel bio-based tissue glue for Perianal Fistulas in Crohn's Disease: A Low-Cost Rodent model studyECCO'25Year: 2025
Authors: Raghunathan, N.(1);Tokala, R.(2);Nagendra, B.(2);Pillikala, M.(2);Bera, A.K.(3);Adhikari, J.(3);Reddy, H.(1);B Lakshmi, J.(3);Midde, S.(4);Singh, J.(5);Chavan, S.(3);Patel, R.(1);Sekaran, A.(4);Mitnala, S.(2);Pati, F.(3);Banerjee, R.(1)*;
(1)Asian Institute of Gastroenterology, IBD Centre, Hyderabad, India;(2)Asian Institute of Gastroenterology, Asian Healthcare Foundation, Hyderabad, India;(3)IIT Hyderabad, Biomedical Engineering, Hyderabad, India;(4)Asian Institute of Gastroenterology, Pathology, Hyderabad, India;(5)Asian Institute of Gastroenterology, Radiology, Hyderabad, India;
1.Bera, A.K. et al. BioScience.2022
2. Ling Li et al. Sci. Adv. 2023
3.Singh A. et al. Inflamm Bowel Dis. 2023
P0156: Plasma immune protein profiles in therapy-naïve ulcerative colitis relate to extent of affected tissue and density of intestinal infiltration, differentiating patients with discreet disease coursesECCO'25Year: 2025
Authors: Calado, B.(1)*;Heredia, M.(1);Charrout, M.(2);Klomberg, R.C.W.(3);Barendregt, D.(1);Hulleman-van Haaften, D.H.(1);Tuk, B.(1);van Berkel, L.A.(1);Folly, B.B.(1);Escher, J.C.(3);de Ridder, L.(3);Samsom, J.N.(1);
(1)Erasmus University Medical Center, Laboratory of Pediatrics- division Gastroenterology and Nutrition, Rotterdam, The Netherlands;(2)Delft University of Technology, Delft Bioinformatics Lab, Delft, The Netherlands;(3)Erasmus University Medical Center-Sophia Children’s Hospital, Department of Pediatric Gastroenterology, Rotterdam, The Netherlands;
P0158: Immune profiles of Inflammatory Bowel Disease and Spondyloarthritis call for personalized medicineECCO'25Year: 2025
Authors: Veltkamp, S.(1)*;van Gaalen, F.A.(2);Samsom, J.N.(3);van der Meulen-de Jong, A.E.(1);Voorneveld, P.W.(1);
(1)Leiden University Medical Center LUMC, Gastroenterology and Hepatology, Leiden, The Netherlands;(2)Leiden University Medical Center LUMC, Rheumatology, Leiden, The Netherlands;(3)Erasmus University Medical Center - Sophia Children's Hospital, Lab of Pediatrics- div. Gastroenterol & Nutrition- on behalf of the Dutch TIMID consortium, Rotterdam, The Netherlands;
1. Karreman, M.C., et al., The Prevalence and Incidence of Axial and Peripheral Spondyloarthritis in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. J Crohns Colitis, 2017. 11(5): p. 631-642.
2. Stolwijk, C., et al., Global Prevalence of Spondyloarthritis: A Systematic Review and Meta-Regression Analysis. Arthritis Care Res (Hoboken), 2016. 68(9): p. 1320-31.
3. van Erp, S.J., et al., Classifying Back Pain and Peripheral Joint Complaints in Inflammatory Bowel Disease Patients: A Prospective Longitudinal Follow-up Study. J Crohns Colitis, 2016. 10(2): p. 166-75.
4. Marques, M.L., et al., Can rheumatologists unequivocally diagnose axial spondyloarthritis in patients with chronic back pain of less than 2 years duration? Primary outcome of the 2-year SPondyloArthritis Caught Early (SPACE) cohort. Ann Rheum Dis, 2024. 83(5): p. 589-598.
P0159: Effects of Transcranial Direct Current Stimulation (tDCS) on enteric nervous system (ENS) gene expression and intestinal barrier in chronic DSS colitisECCO'25Year: 2025
Authors: Wiese, J.J.(1);Manna, S.(1);Bubeck, M.(2);Patankar, J.(2);Siegmund, B.(1);Prüß, M.S.(1);Hering, N.(3);Schumann, M.(1)*;
(1)Charité – University Medicine Berlin, Department of Gastroenterology- Rheumatology and Infectious Diseases, Berlin, Germany;(2)University Hospital Erlangen, Dept. of Internal Medicine 1, Erlangen, Germany;(3)Charité – University Medicine Berlin, Department for Visceral Surgery, Berlin, Germany;
Neeb et al., Brain Stimulation, 2019
P0160: Vitamin D and FGF-19 in patients with Inflammatory Bowel DiseaseECCO'25Year: 2025
Authors: Topalova-Dimitrova, A.(1)*;Dimitrov, I.(2);Nikolov, R.(3);Spasova, Z.(3);
(1)University Hospital " Saint Ivan Rilski"- Sofia- Bulgaria, Gastroenterology, Sofia, Bulgaria;(2)University Hospital "Tsarica Yoanna ISUL", General Surgery, Sofia, Bulgaria;(3)University Hospital "Saint Ivan Rilski", Gastroenterology, Sofia, Bulgaria;
[1] Borissova AM, Shinkov A, Vlahov J, Dakovska L, Todorov T, Svinarov D, Kassabova L.Vitamin D status in Bulgaria--winter data. Arch Osteoporos. 2013;8:133. doi: 10.1007/s11657-013-0133-4. Epub 2013 Mar 23. PMID: 23526032.
[2] Garg M, Rosella O, Lubel JS, Gibson PR. Association of circulating vitamin D concentrations with intestinal but not systemic inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2013 Nov;19(12):2634-43. doi: 10.1097/01.MIB.0000436957.77533.b2. PMID: 24105392.
[3] Battat R, Duijvestein M, Vande Casteele N, et al. Serum Concentrations of 7α-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2019;17(13):2722-2730.e4. doi:10.1016/j.cgh.2018.11.012
[4] Łukawska A, Mulak A. Serum fibroblast growth factor 19 level correlates inversely with clinical and endoscopic activity of inflammatory bowel disease. Adv Clin Exp Med. 2024 Mar 26. doi: 10.17219/acem/184132. Epub ahead of print. PMID: 38530319.
P0161: The primary sclerosing cholangitis and ulcerative colitis colonic mucosa defined through paired microbial and single-cell RNA sequencingECCO'25Year: 2025
Authors: Tearle, J.(1,2)*;Zhang, F.(3);Jackson, K.(4);Malhotra, P.(1);Tavakoli, P.(3);Koentgen, S.(3);Warren, J.(5);Williams, C.(6);Haque, A.(6,7);Arzivian, A.(8);Tedla, N.(2);Kim, A.(8);King, H.(7,9);Hold, G.(3);Ghaly, S.(8,10);James, K.(1,2);
(1)Garvan Institute of Medical Research, Translational Genomics Program, Darlinghurst, Australia;(2)University of New South Wales, School of Biomedical Sciences, Sydney, Australia;(3)University of New South Wales, Microbiome Research Centre, Sydney, Australia;(4)Garvan Institute of Medical Research, Immune Biotherapies Program, Darlinghurst, Australia;(5)Garvan Institute of Medical Research, Cellular Genomics Platform, Darlinghurst, Australia;(6)The Peter Doherty Institute for Infection and Immunity, Department of Microbiology and Immunology, Parkville, Australia;(7)University of Melbourne, Medicine- Dentistry and Health Sciences, Parkville, Australia;(8)University of New South Wales, St. Vincent's Clinical School, Sydney, Australia;(9)Walter and Eliza Hall Institute of Medical Research, Epigenetics and Development Division, Parkville, Australia;(10)St. Vincent’s Hospital Sydney, Department of Gastroenterology and Hepatology, Darlinghurst, Australia;
P0162: Distinct mucin RNA isoform expression in the blood of Inflammatory Bowel Disease patients with variable degree of inflammationECCO'25Year: 2025
Authors: Arras, W.(1)*;Jauregui-Amezaga, A.(2);Oosterlinck, B.(1);Macken, E.(2);Somers, M.(2);De Man, J.(1);De Winter, B.(1);Smet, A.(1);
(1)University of Antwerp, Medicine and health sciences, Wilrijk, Belgium;(2)University Hospital Antwerp, Gastroenterology, Wilrijk, Belgium; Laboratory of experimental medicine and pediatrics
[1] Arras, W., Breugelmans, T., Oosterlinck, B., De Man, J. G., Malhotra-Kumar, S., Abrams, S., ... & Smet, A. (2024). The intestinal mucin isoform landscape reveals region-specific biomarker panels for inflammatory bowel disease patient stratification. Journal of Crohn's and Colitis, jjae155.
P0164: Lauric Acid in Inflammatory Bowel Disease: Balancing Fibrosis Modulation and epithelial-mesenchymal transition ActivationECCO'25Year: 2025
Authors: Patel, J.(1);Cejudo-Garcés, A.(1);Jarén, A.(1)*;Macias-Ceja, D.C.(1);López, A.(2,3);Manresa, M.(4);Calatayud, S.(1,5);Barrachina, M.D.(1,5);Cosin-Roger, J.(1,5);Ortiz-Masiá, D.(5,6,7);
(1)Universitat de València, Pharmacology department, Valencia, Spain;(2)Universitat de València, Medicina department, Valencia, Spain;(3)Hospital Universitario Doctor Peset, Digestivo, Valencia, Spain;(4)University College Dublin, School of Biomolecular and Biomedical Science, Dublin, Spain;(5)Centro de investigaciones en red CIBER, Enfermedades hepáticas y digestivas, Valencia, Spain;(6)Universitat de València, Medicine department, Valencia, Spain;(7)Grupo español de trabajo en enfermedad de Crohn y Colitis GETECCU, Grupo de investigación básica y traslacional, Madrid, Spain;
Bauset C, Carda-Diéguez M, Cejudo-Garcés A, Buetas E, Seco-Cervera M, Macias-Ceja DC, Navarro-Vicente F, Esplugues JV, Calatayud S, Mira Á, Ortiz-Masiá D, Barrachina MD, Cosín-Roger J. A disturbed metabolite-GPCR axis is associated with microbial dysbiosis in IBD patients: Potential role of GPR109A in macrophages. Biochim Biophys Acta Mol Basis Dis. 2024 Dec;1870(8):167489. doi: 10.1016/j.bbadis.2024.167489. Epub 2024 Sep 2. PMID: 39233260.
P0165: A highly miniaturized ingestible sensor for measuring gut health along the GI tractECCO'25Year: 2025
Authors: Even, A.(1,2)*;Minderhoud, R.(1,3,4,5);Torfs, T.(6);Leonardi, F.(1,2);van Heusden, A.(1,2);Sijabat, R.(1,2);Firfilionis, D.(1,2);Dario Castro Miller, I.(6);Rammouz, R.(6);Teichmann, T.(1,2);van Bergen, R.(1,2);Vermeeren, G.(7);Capuano, E.(1,4);Armstrong, R.(1,2);Mathwig, K.(1,2);de Vries, S.(1,3);Goris, A.(1,2);Van Helleputte, N.(6);Hooiveld, G.(1,5);Van Hoof, C.(1,2,6);
(1)OnePlanet Research Center, OnePlanet, Wageningen, The Netherlands;(2)imec, the Netherlands, Wageningen, The Netherlands;(3)Wageningen University & Research, Animal Nutrition Group- Department of Animal Sciences, Wageningen, The Netherlands;(4)Wageningen University & Research, Food Quality and Design Group, Wageningen, The Netherlands;(5)Wageningen University & Research, Division of Human Nutrition and Health, Wageningen, The Netherlands;(6)imec, Belgium, Leuven, Belgium;(7)Ghent University, Department of Information technology, Ghent, Belgium;
1. Campbell EL, Colgan SP. Control and dysregulation of redox signalling in the gastrointestinal tract. Nat Rev Gastroenterol Hepatol. 2019;16(2):106-120. doi:10.1038/s41575-018-0079-5
2. Bourgonje AR, Feelisch M, Faber KN, Pasch A, Dijkstra G, van Goor H. Oxidative Stress and Redox-Modulating Therapeutics in Inflammatory Bowel Disease. Trends Mol Med. 2020;26(11):1034-1046. doi:10.1016/j.molmed.2020.06.006
P0166: Changes in bone mineral density in young patients with inflammatory bowel diseases.ECCO'25Year: 2025
Authors: Myasoutova, E.(1)*;Shamsutdinova, N.(2);Abdulganieva, D.(2);
(1)Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan- Kazan, Therapy, Kazan, Russian Federation;(2)Kazan State Medical University, Therapy, Kazan, Russian Federation;
1. Kreienbuehl A. S. et al. Bone health in patients with inflammatory bowel disease //Swiss medical weekly. – 2024. – Т. 154. – №. 3407. DOI: 10.57187/s.3407
2. A.Kh. RAMAZANOVA, I.G. MUSTAFIN, A.Kh. ODINTSOVA, R.M. NABIULLINA, D.T. SIRAZETDINOV, D.I. ABDULGANIEVA Inflammatory bowel diseases: epidemiology and development of thromboembolic complications, Practical medicine №4 (96) 08/2016/volume 2; 96: 88-91
P0167: Circular extrachromosomal DNA (eccDNA): a potential diagnostic and prognostic tool to be introduced into the clinical practice of Inflammatory Bowel DiseaseECCO'25Year: 2025
Authors: Foscarini, E.(1)*;Emoli, V.(1);Petito, V.(1);Di Vincenzo, F.(1);Masi, L.(1);Troisi, S.(1);Pane, C.(1);Piazzesi, A.(2);Turchini, L.(1);Pugliese, D.(1);Laterza, L.(1);Lopetuso, L.R.(3);Gerovska, D.(4);Arauzo , M.(4);Putignani, L.(2);Regenberg, B.(5);Gasbarrini , A.(6);Scaldaferri, F.(1);
(1)CeMAD Translational Research Laboratory- Digestive Desease Center, Department of Medical and Surgical Science- Fondazione Policlinico Universitario A. Gemelli- IRCCS, Rome, Italy;(2)Unit of Microbiology and Diagnostic Immunology- Unit of Microbiomics and Immunology- Rheumatology and Infectious Diseases Research Area- Unit of Human Microbiome, Bambino Gesù Children's Hospital- IRCCS, Rome, Italy;(3)‘G. D’Annunzio’ University of Chieti-Pescara, Department of Medicine and Ageing Sciences, Chieti, Italy;(4)Biodonostia Health Research Institute, Computational Biology and Systems Biomedicine- Calle Doctor Begiristain s/n- 20014, San Sebastian, Spain;(5)University of Copenhagen, Department of Biology- SECTION FOR ECOLOGY AND EVOLUTION, Copenhagen, Denmark;(6)Catholic University of the Sacred Heart, Department of Translational Medicine and Surgery, Rome, Italy;
Fundings: European Union’s Horizon 2020 Research and Innovation Programme (899417)
P0168: Differential expression of enteric glial cell markers in inflamed and non-inflamed tissue of patients with Ulcerative Colitis during clinically active disease and remissionECCO'25Year: 2025
Authors: Beaudeau, J.(1);Katinios, G.(2);Biskou, O.(1);Lindqvist, C.M.(3);Walter, S.A.(2);Bednarska, O.(2);Söderholm, J.D.(1);Salomon, B.(3);Halfvarson, J.(4);Schoultz, I.(3)*;Hjortswang, H.(2);Keita, Å.V.(1);
(1)Linköping University, Department of Biomedical and Clinical Sciences, Linköping, Sweden;(2)Linköping University Hospital, Department of Gastroenterology, Linköping, Sweden;(3)Örebro University, School of Medical Sciences, Örebro, Sweden;(4)Örebro University, Department of Gastroenterology, Örebro, Sweden;
P0169: Relapse of ulcerative colitis on dose reduction of tofacitinib is associated with markers of T-cell activation but not clinical features: a prospective, multicentre observational studyECCO'25Year: 2025
Authors: Honap, S.(1,2)*;Kim, S.(1);Whettlock, E.(1);Centritto, A.(3);Seah, D.(3);Baillie, S.(2);Luber, R.(3);Choong, L.M.(4);Samaan, M.(3);Pavlidis, P.(1,4);Patel, K.(2);Dart, R.(1,3);John, S.(1);Irving, P.(1,3);
(1)King’s College London, School of Immunology and Microbial Sciences, London, United Kingdom;(2)St George’s University Hospital NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom;(3)Guy’s and St Thomas’ NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom;(4)King’s College London, Department of Gastroenterology, London, United Kingdom;
